本文選題：miR-139-5p + Cdc42　； 參考：《蘇州大學(xué)》2016年博士論文

【摘要】：骨肉瘤是一種起源于間葉組織的骨骼系統(tǒng)惡性腫瘤,其發(fā)病率和死亡率在原發(fā)性骨腫瘤中均居首位。骨肉瘤多發(fā)于15-25周歲的青少年,其發(fā)展進(jìn)程快,轉(zhuǎn)移及復(fù)發(fā)率高,患者生存旅較低,行單一手術(shù)切除術(shù)治療的患者5年生存率僅為15-20%,已成為青少年健康的一大威脅。隨著醫(yī)療技術(shù)的迅猛發(fā)展,新輔助放化療聯(lián)合保肢術(shù)替代截肢術(shù)成為骨肉瘤治療的主要外科手段,雖然患者預(yù)后水平有所提高,但放化療并不具有靶向性,并不能有效清除腫瘤細(xì)胞,患者術(shù)后復(fù)發(fā)率較高,且保肢術(shù)后還需輔助骨組織重建術(shù),價(jià)格昂貴,給患者帶來(lái)一定的經(jīng)濟(jì)壓力。目前,骨肉瘤新型治療手段如免疫療法、介入治療、中醫(yī)藥治療及基因靶向治療成為攻克骨肉瘤的突破口。其中基因靶向治療可靶向在骨肉瘤發(fā)展進(jìn)程中起重要功能的癌相關(guān)基因,從而抑制腫瘤細(xì)胞增殖、遷移和侵襲等惡性生物學(xué)特性,而成為有效治愈骨肉瘤的新希望。因此,進(jìn)一步揭示骨肉瘤發(fā)生發(fā)展中的分子機(jī)制全貌,探索新的分子治療靶點(diǎn),為基因靶向治療提供理論依據(jù)和數(shù)據(jù)支持,具有重要的臨床意義和科學(xué)價(jià)值。隨著第二代高通量測(cè)序技術(shù)的成熟和廣泛應(yīng)用,針對(duì)腫瘤組織和細(xì)胞的測(cè)序數(shù)據(jù)如外顯子測(cè)序、轉(zhuǎn)錄組測(cè)序、miRNAs測(cè)序、lnc RNA測(cè)序和單細(xì)胞測(cè)序數(shù)據(jù)等為基因靶向治療的研究提供了可靠的數(shù)據(jù)支持,腫瘤學(xué)研究由此迎來(lái)了“數(shù)據(jù)爆炸”時(shí)代。在當(dāng)今大數(shù)據(jù)時(shí)代,一系列整合了大量腫瘤樣本的基因測(cè)序數(shù)據(jù)及臨床數(shù)據(jù)的數(shù)據(jù)庫(kù)如TCGA、Oncomine等也應(yīng)運(yùn)而生,被廣泛的應(yīng)用到腫瘤學(xué)的研究中來(lái)。TCGA數(shù)據(jù)庫(kù)是當(dāng)今最大的數(shù)據(jù)庫(kù),其涵蓋全球范圍內(nèi)29種類型的腫瘤超過(guò)1萬(wàn)例樣本的外顯子測(cè)序數(shù)據(jù)、SNP數(shù)據(jù)、CMV數(shù)據(jù)及全面的臨床數(shù)據(jù),成為腫瘤學(xué)研究的一把利劍。目前圍繞TCGA數(shù)據(jù)庫(kù)展開的相關(guān)研究發(fā)表在《Science》、《Nature》、《PNS》等一系列重量級(jí)科學(xué)刊物。但利用TCGA大數(shù)據(jù)進(jìn)行骨肉瘤的研究則未見報(bào)道。因此,在當(dāng)今大數(shù)據(jù)時(shí)代,如何運(yùn)用腫瘤大數(shù)據(jù)對(duì)骨肉瘤進(jìn)行深入的研究,進(jìn)一步完善骨肉瘤發(fā)生發(fā)展的分子機(jī)制,成為當(dāng)今腫瘤學(xué)研究的一大趨勢(shì)。microRNAs是一類長(zhǎng)度約為21-23nt的在物種間具有高度保守性的非編碼RNA,之前的研究認(rèn)為miRNA是一種不具備功能的基因轉(zhuǎn)錄的“垃圾產(chǎn)物”,隨著深入的研究,人們逐漸發(fā)現(xiàn),miRNA可以6-8個(gè)堿基不完全互補(bǔ)配對(duì)的方式與靶基因3’UTR區(qū)域結(jié)合,發(fā)揮對(duì)基因表達(dá)負(fù)向調(diào)控的作用。因此,miRNA在調(diào)控細(xì)胞的各項(xiàng)生理功能如增殖、分化、凋亡衰老方面具有重要的功能。并于2002年被《Science》雜志評(píng)為十大科技突破第一名。目前在哺乳動(dòng)物中已鑒定出的miRNA多達(dá)上千條序列,并且仍不斷有新的miRNAs被發(fā)現(xiàn)。近年來(lái),隨著對(duì)miRNA在腫瘤學(xué)研究的不斷深入,人們逐漸發(fā)現(xiàn)腫瘤中有許多miRNA對(duì)癌相關(guān)基因具有重要的調(diào)控作用,在腫瘤的發(fā)生發(fā)展中扮演著重要的角色,被認(rèn)為是治療腫瘤的潛在的分子靶點(diǎn)。因此,進(jìn)一步探索和研究在骨肉瘤發(fā)生發(fā)展中起關(guān)鍵性調(diào)控作用的miRNAs,將對(duì)于進(jìn)一步明確骨肉瘤發(fā)生發(fā)展中伴隨的分子機(jī)制,以及探索新的分子治療靶點(diǎn)具有重要的科學(xué)意義。第一部分基于TCGA腫瘤數(shù)據(jù)分析miR-139在骨肉瘤中的表達(dá)及其表觀調(diào)控機(jī)制研究在本部分的研究中,我們利用TCGA腫瘤數(shù)據(jù)庫(kù)中的骨肉瘤miRNA芯片數(shù)據(jù),篩選在骨肉瘤中發(fā)生顯著差異表達(dá)的miRNAs,發(fā)現(xiàn)發(fā)生顯著下調(diào)表達(dá)的miRNAs有70條,發(fā)生顯著上調(diào)表達(dá)的miRNAs有115條。在顯著上調(diào)的miRNAs中,miR-139-5p是下調(diào)最為顯著且未在骨肉瘤中有報(bào)道的miRNA。我們采用q RT-PCR檢測(cè)了骨肉瘤組織及細(xì)胞系中miR-139-5p的表達(dá),結(jié)果進(jìn)一步說(shuō)明miR-139-5p在骨肉瘤中發(fā)生了下調(diào)表達(dá)。為了探究miR-139-5p在骨肉瘤中發(fā)生下調(diào)表達(dá)的分子機(jī)制,我們采用CHIP實(shí)驗(yàn)檢測(cè)了miR-139啟動(dòng)子區(qū)組蛋白的甲基化及乙酰化修飾情況發(fā)現(xiàn),miR-139在骨肉瘤中的下調(diào)表達(dá)是由miR139啟動(dòng)子區(qū)組蛋白H3K27、H3K9甲基化水平上調(diào),H3K4甲基化水平下調(diào)以及H3乙酰化水平下調(diào)所介導(dǎo)的。此外,我們結(jié)合TCGA數(shù)據(jù)庫(kù)中骨肉瘤樣本的臨床數(shù)據(jù),分析了miR-139-5p表達(dá)與患者生存期的關(guān)系發(fā)現(xiàn),miR-139-5p高表達(dá)患者的生存期顯著高于低表達(dá)患者。通過(guò)以上結(jié)果,我們初步推斷miR-139-5p在骨肉瘤發(fā)生發(fā)展中具有重要的作用。第二部分miR-139-5p對(duì)骨肉瘤惡行生物學(xué)表型的調(diào)控作用及其分子機(jī)制研究為了研究miR-139-5p在骨肉瘤發(fā)生發(fā)展中的作用,我們首先采用q RT-PCR檢測(cè)了miR-139-5p mimics的轉(zhuǎn)染效率。結(jié)果顯示,轉(zhuǎn)染miR-139-5p mimics可顯著提高骨肉瘤細(xì)胞MG63及U20S中miR-139-5p水平。接下來(lái),我們采用CCK8實(shí)驗(yàn)檢測(cè)了miR-139-5p對(duì)骨肉瘤增殖的影響發(fā)現(xiàn),miR-139-5p可顯著抑制骨肉瘤的增殖。采用Transwell檢測(cè)miR-139-5p對(duì)骨肉瘤細(xì)胞遷移和侵襲的影響發(fā)現(xiàn),miR-139-5p可顯著抑制骨肉瘤細(xì)胞的遷移和侵襲。此外,構(gòu)建裸鼠皮下抑制瘤模型,體內(nèi)過(guò)表達(dá)miR-139-5p后發(fā)現(xiàn),miR-139-5p可顯著抑制瘤體生長(zhǎng)。因此,我們得出結(jié)論:miR-139-5p可顯著抑制骨肉瘤的發(fā)生發(fā)展。為了探究miR-139-5p發(fā)揮抑瘤作用的分子機(jī)制,我們首先采用Targetscan預(yù)測(cè)了miR-139-5p的靶基因發(fā)現(xiàn),miR-139-5p可靶向Cdc42 m RNA 3’UTR序列。為了進(jìn)一步探究miR-139-5p對(duì)Cdc42 m RNA 3’UTR序列的靶向作用,我們構(gòu)建了Cdc42m RNA 3’UTR區(qū)45-52位點(diǎn)的Luciferase雙熒光報(bào)告載體,轉(zhuǎn)染miR-139-5p后發(fā)現(xiàn)miR-139-5p可顯著抑制熒光生成。以上結(jié)果說(shuō)明miR-139-5p可靶向Cdc42 m RNA3’UTR 45-52位點(diǎn)。為了進(jìn)一步探究miR-139-5p對(duì)Cdc42是否有負(fù)向調(diào)控作用及其作用機(jī)制,我們檢測(cè)了轉(zhuǎn)染miR-139-5p后,骨肉瘤細(xì)胞Cdc42 m RNA及蛋白的表達(dá)發(fā)現(xiàn),miR-139-5p并不抑制Cdc42 m RNA水平,可顯著抑制Cdc42蛋白的表達(dá)。通過(guò)以上結(jié)果,我們得出結(jié)論:miR-139-5p可通過(guò)抑制Cdc42 m RNA的翻譯從而對(duì)Cdc42基因表達(dá)起負(fù)向調(diào)控作用。第三部分Cdc42對(duì)骨肉瘤惡行生物學(xué)表型的調(diào)控作用研究在本部分中,我們探究了Cdc42基因在骨肉瘤中的表達(dá)及其對(duì)骨肉瘤惡性生物學(xué)表型的調(diào)控作用。首先分析了TCGA數(shù)據(jù)庫(kù)中骨肉瘤RNA-Seq數(shù)據(jù)發(fā)現(xiàn),Cdc42m RNA并未在骨肉瘤中發(fā)生差異表達(dá),采用q RT-PCR及Westernblot分別檢測(cè)了骨肉瘤組織和細(xì)胞系中Cdc42 m RNA和蛋白表達(dá)發(fā)現(xiàn),Cdc42 m RNA并未在骨肉瘤中發(fā)生差異表達(dá),但Cdc42蛋白在骨肉瘤中發(fā)生了顯著的上調(diào)表達(dá)。以上結(jié)果說(shuō)明,Cdc42在骨肉瘤中發(fā)生顯著的上調(diào)表達(dá),其上調(diào)表達(dá)主要發(fā)生在轉(zhuǎn)錄后的調(diào)控,miR-139-5p作為Cdc42轉(zhuǎn)錄后的調(diào)控因子,在調(diào)控Cdc42表達(dá)上具有重要的作用。接下來(lái)我們探究了Cdc42對(duì)骨肉瘤細(xì)胞增殖和遷移的影響。CCK8結(jié)果顯示,沉默Cdc42表達(dá)可顯著抑制骨肉瘤細(xì)胞的增殖;劃痕實(shí)驗(yàn)結(jié)果顯示,Cdc42沉默后,骨肉瘤細(xì)胞的遷移能力降低。通過(guò)以上結(jié)果,我們得出Cdc42可促進(jìn)骨肉瘤細(xì)胞的增殖和分化。綜上所述,miR-139-5p在骨肉瘤發(fā)生發(fā)展中發(fā)揮著重要的作用,具體表現(xiàn)為通過(guò)負(fù)向調(diào)控Cdc42基因的表達(dá),從而抑制骨肉瘤的發(fā)生發(fā)展,可以作為治療骨肉瘤潛在的分子靶點(diǎn)。
[Abstract]:Osteosarcoma is a malignant tumor of the skeletal system derived from interleaf tissue. The incidence and mortality of osteosarcoma are the first in primary bone tumors. Osteosarcoma often occurs in adolescents aged 15-25 years, with rapid development, high metastasis and recurrence rate and low survival. The 5 year survival rate of patients treated with single hand surgery is only 15-20%, With the rapid development of medical technology, with the rapid development of medical technology, the combination of neoadjuvant radiotherapy and chemotherapy combined with limb salvage has become the main surgical method for osteosarcoma. Although the prognosis of the patients is improved, the radiotherapy and chemotherapy is not targeted, and the tumor cells can not be effectively removed, and the recurrence rate of the patients is higher. It is also necessary to assist the reconstruction of bone tissue after limb salvage, which is expensive and brings some economic pressure to the patients. At present, the new treatment of osteosarcoma, such as immunotherapy, interventional therapy, Chinese medicine treatment and gene targeting therapy, has become the breakthrough of osteosarcoma. Gene targeting therapy can be used to play an important role in the process of osteosarcoma development. The function of cancer related genes, thus inhibiting tumor cell proliferation, migration and invasion and other malignant biological characteristics, and become a new hope to effectively cure osteosarcoma. Therefore, further reveal the molecular mechanism of osteosarcoma development, explore new molecular therapeutic targets, provide theoretical basis and data support for gene targeting therapy. Important clinical significance and scientific value. With the mature and extensive application of the second generation high-throughput sequencing technology, the research on tumor tissue and cell sequencing data, such as exon sequencing, transcriptional sequencing, miRNAs sequencing, LNC RNA sequencing and single cell sequencing data, provides reliable data support for gene targeting therapy, oncology In today's big data age, a series of data databases such as TCGA and Oncomine, which integrate a large number of tumor samples, such as TCGA, and clinical data, are also widely used in oncology research to be the largest database today, covering the global scope. Exon sequencing data, SNP data, CMV data, and comprehensive clinical data of 29 types of internal tumor types have become a sharp sword in oncology research. A series of scientific publications on , , , etc. are published around the TCGA database. However, osteosarcoma with large TCGA data is used for osteosarcoma. Therefore, in today's big data age, how to use tumor large data to study osteosarcoma, further improve the molecular mechanism of osteosarcoma development, and become a major trend in oncology research today.MicroRNAs is a class of highly conserved non coded R with a length of about 21-23nt. NA, previous studies suggest that miRNA is a "junk product" that does not have functional gene transcription. With further research, people have gradually found that miRNA can combine the 6-8 base pairs with the target gene 3 'UTR region to play the role in the negative regulation of gene expression. Therefore, miRNA regulates every cell in the cell. Physical function, such as proliferation, differentiation and apoptosis, has important functions. In 2002, it was first named ten major scientific and technological breakthroughs in magazine. At present, up to thousands of miRNA sequences have been identified in mammals, and new miRNAs has been found. In recent years, with the deepening of oncology research on miRNA, people We have gradually found that many miRNA plays an important role in the regulation of cancer related genes and plays an important role in the development of cancer. It is considered as a potential molecular target for cancer treatment. Therefore, further exploration and study of the regulatory role of the key role of miRNAs in the development of osteosarcoma will be further clear. The molecular mechanism associated with the development of the osteosarcoma and the exploration of new molecular therapeutic targets are of great scientific significance. Part 1 based on the analysis of TCGA tumor data, the expression of miR-139 in osteosarcoma and its apparent regulation mechanism are studied in this part, and we use the number of miRNA chips in the osteosarcoma in the TCGA tumor database. According to the screening of significant differential expression of miRNAs in osteosarcoma, there were 70 significant down-regulation miRNAs and 115 significant up-regulated miRNAs. In a significantly up-regulated miRNAs, miR-139-5p was the most significant down-regulation and was not reported in osteosarcoma. We used Q RT-PCR to detect osteosarcoma tissues and fines. The expression of miR-139-5p in the cell lines further indicated that miR-139-5p was downregulated in osteosarcoma. In order to explore the molecular mechanism of the down-regulation of miR-139-5p in osteosarcoma, we detected the methylation and acetylation of the histone in the miR-139 promoter region by CHIP test, and miR-139 was found in the osteosarcoma. The expression is mediated by the miR139 promoter histone H3K27, the up regulation of H3K9 methylation level, the downregulation of H3K4 methylation level and the downregulation of H3 acetylation. In addition, we combine the clinical data of the osteosarcoma samples in the TCGA database to analyze the relationship between the expression of miR-139-5p and the survival period of the patients, and the birth of the patients with high expression of miR-139-5p. The survival time is significantly higher than that of the low expression patients. Through the above results, we preliminarily deduce that miR-139-5p plays an important role in the development of osteosarcoma. Second the role of miR-139-5p in the regulation of the biological phenotype of osteosarcoma and its molecular mechanism are studied to study the role of miR-139-5p in the development of osteosarcoma. Q RT-PCR was used to detect the transfection efficiency of miR-139-5p mimics. The results showed that the transfection of miR-139-5p mimics could significantly increase the miR-139-5p level in osteosarcoma cells MG63 and U20S. Next, we detected miR-139-5p on the proliferation of osteosarcoma by CCK8 experiment, and miR-139-5p could significantly inhibit the proliferation of osteosarcoma. The effect of miR-139-5p on the migration and invasion of osteosarcoma cells found that miR-139-5p could significantly inhibit the migration and invasion of osteosarcoma cells. In addition, the subcutaneous tumor model of nude mice was constructed, and after the overexpression of miR-139-5p in the body, miR-139-5p could significantly inhibit the growth of the tumor. Therefore, we conclude that miR-139-5p can significantly inhibit osteosarcoma. Development. In order to explore the molecular mechanism of miR-139-5p playing a tumor suppressor, we first used Targetscan to predict the target gene discovery of miR-139-5p, and miR-139-5p can target the Cdc42 m RNA 3 'UTR sequence. In order to further explore the target of miR-139-5p to Cdc42 m RNA 3' sequence, we construct 45-52 bits. Luciferase double fluorescent report carrier, miR-139-5p can significantly inhibit fluorescence generation after transfection of miR-139-5p. The above results show that miR-139-5p can target Cdc42 m RNA3 'UTR 45-52 site. In order to further explore the negative regulation of miR-139-5p on Cdc42 and its mechanism of action, we detected osteosarcoma after miR-139-5p transfection. The expression of Cdc42 m RNA and protein found that miR-139-5p did not inhibit the Cdc42 m RNA level and could significantly inhibit the expression of Cdc42 protein. Through the above results, we concluded that miR-139-5p can be used to regulate the expression of the gene by inhibiting the translation of Cdc42 m RNA. The third part of the biological phenotype of osteosarcoma is the biological phenotype of osteosarcoma. In this part, we explored the expression of Cdc42 gene in osteosarcoma and its regulatory role in the malignant biological phenotype of osteosarcoma. First, we analyzed the RNA-Seq data of osteosarcoma in the TCGA database, and Cdc42m RNA was not expressed differently in osteosarcoma, and the bone was detected by Q RT-PCR and Westernblot, respectively. The expression of Cdc42 m RNA and protein in sarcomas and cell lines found that Cdc42 m RNA did not express differential expression in osteosarcoma, but the expression of Cdc42 protein in osteosarcoma was significantly up-regulated. The above results indicated that Cdc42 was significantly up-regulated in osteosarcoma, and its up regulation was mainly regulated after transcriptional regulation, miR-139-5p As a regulatory factor after Cdc42 transcriptional regulation, it plays an important role in regulating the expression of Cdc42. Then we explored the effect of Cdc42 on the proliferation and migration of osteosarcoma cells..CCK8 results showed that silent Cdc42 expression significantly inhibited the proliferation of osteosarcoma cells; the scratch test showed that the migration ability of osteosarcoma cells after Cdc42 was silent. Through the above results, we conclude that Cdc42 can promote the proliferation and differentiation of osteosarcoma cells. To sum up, miR-139-5p plays an important role in the development of osteosarcoma, which is manifested by negative regulation of the expression of Cdc42 gene, thus inhibiting the occurrence and development of osteosarcoma, and can be used as a potential molecular target for the treatment of osteosarcoma. Point.

【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類號(hào)】：R738.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李繼慶;高危骨肉瘤的研究進(jìn)展[J];中國(guó)矯形外科雜志;2003年13期

2 胡牧,錢光,梅炯,蔡宣松;骨肉瘤的肺外轉(zhuǎn)移[J];國(guó)外醫(yī)學(xué).骨科學(xué)分冊(cè);2004年03期

3 劉洪彪,葉小娟,占宏偉,孫達(dá);骨肉瘤放射性核素骨顯像50例分析[J];實(shí)用腫瘤雜志;2005年01期

4 周忠;林建華;;骨肉瘤的中西醫(yī)結(jié)合治療研究進(jìn)展[J];甘肅中醫(yī);2006年03期

5 楊茂偉;王加璐;王旭東;羅輯;;X線表現(xiàn)陰性骨肉瘤的早期診斷[J];中國(guó)腫瘤臨床;2008年22期

6 張淑彬;吳朝平;;骨肉瘤患者父母的焦慮狀況調(diào)查分析[J];華西醫(yī)學(xué);2008年06期

7 徐新華;周福祥;;20例兒童骨肉瘤的臨床治療[J];中醫(yī)兒科雜志;2008年02期

8 王建華;林艷;賈衛(wèi)斗;云得才;許英杰;鄭鐵鋼;;骨肉瘤的診斷與治療[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2010年30期

9 李毅星;閆文濤;楊本華;;骨肉瘤31例早期診斷分析[J];中國(guó)煤炭工業(yè)醫(yī)學(xué)雜志;2010年11期

10 徐欣華;李曉琴;楊榮;劉芳;康雅瓊;何欣;尚立娜;;血小板衍生生長(zhǎng)因子受體-a在骨肉瘤中的表達(dá)及意義[J];甘肅醫(yī)藥;2012年11期

相關(guān)會(huì)議論文 前10條

1 許少健;張葆青;劉金文;石宇雄;黃永明;;16例骨肉瘤患者化療期間的相關(guān)心理分析[A];中華中醫(yī)藥學(xué)會(huì)骨傷分會(huì)第四屆第二次會(huì)議論文匯編[C];2007年

2 馬月新;;骨肉瘤化療期間的護(hù)理對(duì)策[A];全國(guó)腫瘤護(hù)理學(xué)術(shù)交流暨專題講座會(huì)議論文匯編[C];2005年

3 陳秋;王達(dá)輝;閔若良;馬巍;;應(yīng)用大段異體骨治療兒童骨肉瘤的初步體會(huì)[A];2007年浙江省醫(yī)學(xué)會(huì)骨科學(xué)學(xué)術(shù)會(huì)議暨浙江省抗癌協(xié)會(huì)骨軟腫瘤學(xué)術(shù)會(huì)議論文匯編[C];2007年

4 鄭進(jìn)佑;;骨肉瘤的現(xiàn)代外科治療概況[A];全國(guó)中西醫(yī)結(jié)合學(xué)會(huì)骨傷科專業(yè)委員會(huì)第十二次學(xué)術(shù)年會(huì)浙江省中西醫(yī)結(jié)合學(xué)會(huì)骨傷科專業(yè)委員會(huì)第十次學(xué)術(shù)年會(huì)論文匯編[C];2004年

5 余寧先;;骨肉瘤病人家屬的心理護(hù)理[A];全國(guó)腫瘤護(hù)理學(xué)術(shù)交流暨專題講座會(huì)議論文匯編[C];2004年

6 汪偉;陳文直;周潔敏;白玲;劉文英;葉慧義;;高強(qiáng)度聚焦超聲治療骨肉瘤的臨床應(yīng)用研究[A];中華醫(yī)學(xué)會(huì)超聲醫(yī)學(xué)新進(jìn)展學(xué)術(shù)會(huì)議論文匯編[C];2004年

7 曹慶選;李文華;曹來(lái)賓;夏寶樞;;中藥治愈骨肉瘤的中醫(yī)研究與影像學(xué)對(duì)照[A];第十次全國(guó)中西醫(yī)結(jié)合影像學(xué)術(shù)研討會(huì)暨全國(guó)中西醫(yī)結(jié)合影像學(xué)研究與診斷學(xué)習(xí)班資料匯編[C];2009年

8 王英;肖艦;陳曉華;;骨肉瘤病人癌性疼痛的護(hù)理體會(huì)[A];全國(guó)腫瘤護(hù)理學(xué)術(shù)交流暨專題講座會(huì)議論文匯編[C];2003年

9 陳秋;王達(dá)輝;閔若良;馬巍;;大段異體骨治療兒童骨肉瘤的初步應(yīng)用[A];2005'中國(guó)修復(fù)重建外科論壇論文匯編[C];2005年

10 劉巧慧;韓莎莎;;骨肉瘤保肢患者的心理護(hù)理[A];全國(guó)外科、神經(jīng)內(nèi)外科護(hù)理學(xué)術(shù)交流暨專題講座會(huì)議論文匯編[C];2006年

相關(guān)重要報(bào)紙文章 前1條

1 張中橋;骨肉瘤病理基礎(chǔ)與其MRI表現(xiàn)[N];中國(guó)醫(yī)藥報(bào);2004年

相關(guān)博士學(xué)位論文 前10條

1 劉義慶;雄烯二酮衍生物DSTD誘導(dǎo)骨肉瘤細(xì)胞自噬和減輕其耐藥性的研究[D];山東大學(xué);2015年

2 尚永軍;TIM-3在骨肉瘤侵襲轉(zhuǎn)移中的作用及機(jī)制研究[D];延邊大學(xué);2015年

3 禚文昆;MiR-20a調(diào)節(jié)EGR2對(duì)骨肉瘤的影響[D];第四軍醫(yī)大學(xué);2015年

4 高琰;CD44在卵巢癌/骨肉瘤進(jìn)展中的作用及上轉(zhuǎn)換納米逆轉(zhuǎn)腫瘤耐藥的研究[D];鄭州大學(xué);2016年

5 趙加力;B7-H3在骨肉瘤微環(huán)境中的表達(dá)及其作用機(jī)制[D];蘇州大學(xué);2016年

6 林博川;MicroRNA-184在骨肉瘤阿霉素耐藥中的功能與機(jī)制研究[D];南方醫(yī)科大學(xué);2016年

7 包擁政;miR-664調(diào)控靶基因SOX7促進(jìn)MG-63骨肉瘤細(xì)胞體外侵襲和遷移機(jī)理研究[D];南方醫(yī)科大學(xué);2016年

8 陳斌;miR-664下調(diào)靶基因FOXO4促進(jìn)骨肉瘤細(xì)胞惡性增殖及機(jī)制研究[D];南方醫(yī)科大學(xué);2016年

9 閆廣寧;骨肉瘤干細(xì)胞自我更新的調(diào)控機(jī)制及意義[D];第三軍醫(yī)大學(xué);2016年

10 程思;S100A9在骨肉瘤中的表達(dá)和對(duì)骨肉瘤功能作用的影響及相關(guān)機(jī)制的研究[D];重慶醫(yī)科大學(xué);2016年

相關(guān)碩士學(xué)位論文 前10條

1 靳曉建;新輔助化療結(jié)合保肢手術(shù)治療骨肉瘤的臨床療效分析[D];山西醫(yī)科大學(xué);2015年

2 王亞鵬;褪黑素聯(lián)合順鉑、甲氨蝶呤對(duì)骨肉瘤SaOS-2細(xì)胞增殖的影響[D];山東大學(xué);2015年

3 陳記軍;骨肉瘤患者血清中特異性microRNA表達(dá)譜的篩選及其臨床意義的研究[D];南京大學(xué);2013年

4 康學(xué)華;骨肉瘤中WIF-1基因啟動(dòng)子區(qū)異常甲基化及mRNA的表達(dá)研究[D];青島大學(xué);2015年

5 李騰飛;HIF-1α和PTEN在骨肉瘤中的表達(dá)及其臨床意義[D];南華大學(xué);2015年

6 關(guān)國(guó)鋒;CXCR4靶點(diǎn)近紅外光學(xué)分子成像檢測(cè)骨肉瘤原位及肺轉(zhuǎn)移腫瘤病灶的研究[D];第四軍醫(yī)大學(xué);2015年

7 王志濤;CD44s、CD44v6及CD44v9在骨肉瘤、骨巨細(xì)胞瘤及骨軟骨瘤標(biāo)本的表達(dá)及臨床意義[D];吉林大學(xué);2016年

8 榮小麗;LIMK1基因穩(wěn)定轉(zhuǎn)染骨肉瘤耐藥細(xì)胞系的建立及其增殖侵襲能力的研究[D];吉林大學(xué);2016年

9 關(guān)紅亞;miR-192靶向TCF7基因?qū)侨饬黾?xì)胞增殖和侵襲的抑制作用[D];鄭州大學(xué);2016年

10 閆紅衛(wèi);骨肉瘤臨床診治的影像學(xué)檢查優(yōu)化探討[D];廣西醫(yī)科大學(xué);2016年

，

本文編號(hào)：1789635

boshi